Search

Author/Creator George, Jyothis

1. Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME. (11th September 2020)

Authors:
Pellicori, Pierpaolo; Ofstad, Anne Pernille; Fitchett, David; Zeller, Cordula; Wanner, Christoph; George, Jyothis; Zinman, Bernard; Brueckmann, Martina; Lindenfeld, JoAnn
Journal:
ESC heart failure
Issue:
Volume 7:Number 6(2020)
Page Start:
3401
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Issue 2 (9th January 2018)

Authors:
Wanner, Christoph; Lachin, John M.; Inzucchi, Silvio E.; Fitchett, David; Mattheus, Michaela; George, Jyothis; Woerle, Hans J.; Broedl, Uli C.; von Eynatten, Maximilian; Zinman, Bernard
Journal:
Circulation
Issue:
Volume 137:Issue 2(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Empagliflozin as add‐on to linagliptin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52‐week, randomized, placebo‐controlled trial. Issue 9 (1st June 2018)

Authors:
Kawamori, Ryuzo; Haneda, Masakazu; Suzaki, Keiko; Cheng, Gang; Shiki, Kosuke; Miyamoto, Yuki; Solimando, Fernando; Lee, Christopher; Lee, Jisoo; George, Jyothis
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 20:Issue 9(2018)
Page Start:
2200
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial. Issue 9 (5th June 2018)

Authors:
Shimada, Akira; Hanafusa, Toshiaki; Yasui, Atsutaka; Lee, Ganghyuck; Taneda, Yusuke; Sarashina, Akiko; Shiki, Kosuke; George, Jyothis; Soleymanlou, Nima; Marquard, Jan
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 20:Issue 9(2018)
Page Start:
2190
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial. (16th July 2019)

Authors:
Packer, Milton; Butler, Javed; Filippatos, Gerasimos S.; Jamal, Waheed; Salsali, Afshin; Schnee, Janet; Kimura, Karen; Zeller, Cordula; George, Jyothis; Brueckmann, Martina; Anker, Stefan D.; Zannad, Faiez
Other Names:
investigator.; Packer Milton investigator.; Anker Stefan D. investigator.; Butler Javed investigator.; Filippatos Gerasimos investigator.; Zannad Faiez investigator.; George Jyothis investigator.; Brueckmann Martina investigator.; investigator.; Perrone Sergio investigator.; Nicholls Stephen in...
Journal:
European journal of heart failure
Issue:
Volume 21:Number 10(2019)
Page Start:
1270
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial. (16th September 2019)

Authors:
Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos S.; Jamal, Waheed; Salsali, Afshin; Schnee, Janet; Kimura, Karen; Zeller, Cordula; George, Jyothis; Brueckmann, Martina; Zannad, Faiez; Packer, Milton
Other Names:
Packer Milton investigator.; Anker Stefan D. investigator.; Butler Javed investigator.; Filippatos Gerasimos S. investigator.; Zannad Faiez investigator.; George Jyothis investigator.; Brueckmann Martina investigator.; Perrone Sergio investigator.; Nicholls Stephen investigator.; Janssens Stefan ...
Journal:
European journal of heart failure
Issue:
Volume 21:Number 10(2019)
Page Start:
1279
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial. Issue 1 (6th September 2018)

Authors:
Kaku, Kohei; Haneda, Masakazu; Tanaka, Yuko; Lee, Ganghyuck; Shiki, Kosuke; Miyamoto, Yuki; Solimando, Fernando; Lee, Jisoo; Lee, Christopher; George, Jyothis
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 21:Issue 1(2019)
Page Start:
136
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial. (16th June 2021)

Authors:
Verma, Subodh; Leiter, Lawrence A.; Zinman, Bernard; Sharma, Abhinav; Mattheus, Michaela; Fitchett, David; George, Jyothis; Ofstad, Anne Pernille; Kosiborod, Mikhail N.; Wanner, Christoph; Inzucchi, Silvio E.
Journal:
ESC heart failure
Issue:
Volume 8:Number 4(2021)
Page Start:
2603
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗